Treatment for Node-Negative, Hormone-Positive, HER2-Negative Breast Cancer

Endocrine Therapy Options

For postmenopausal women, aromatase inhibitors (AIs) are recommended as first-line endocrine therapy, according to the American Society of Clinical Oncology 1
Ovarian suppression with GnRH agonists may be added to tamoxifen for higher-risk premenopausal patients, as suggested by the American Society of Clinical Oncology 1
Male patients with hormone-positive breast cancer should receive tamoxifen with consideration of GnRH analog, as recommended by the American Society of Clinical Oncology 1
Monitoring for endocrine therapy side effects is essential, including bone health assessment for patients on aromatase inhibitors, according to the American Society of Clinical Oncology 1

Genomic assays (such as Oncotype DX, MammaPrint) should be used to guide adjuvant chemotherapy decisions for patients with node-negative, hormone-positive, HER2-negative breast cancer, as recommended by the American Society of Clinical Oncology 2
Patients with high genomic risk scores should receive chemotherapy followed by endocrine therapy to reduce recurrence risk, according to the American Society of Clinical Oncology 2

Docetaxel-cyclophosphamide (TC) for 4 cycles is recommended as an effective non-anthracycline regimen, as suggested by the American Society of Clinical Oncology 2
Doxorubicin-cyclophosphamide followed by weekly paclitaxel is another standard option, according to the American Society of Clinical Oncology 2
Dose-dense regimens may be considered for higher-risk patients, as recommended by the American Society of Clinical Oncology 2

For low-risk disease, endocrine therapy alone for 5 years is recommended, with postmenopausal women receiving aromatase inhibitors, according to the American Society of Clinical Oncology 1
For intermediate to high-risk disease, adjuvant chemotherapy followed by endocrine therapy is recommended, as suggested by the American Society of Clinical Oncology 2